Current Status: Site-Specific Antibody Drug Conjugates

Antibody drug conjugates (ADCs), a promising class of cancer biopharmaceuticals, combine the specificity of therapeutic antibodies with the pharmacological potency of chemical, cytotoxic drugs. Ever since the first ADCs on the market, a plethora of novel ADC technologies has emerged, covering as div...

Descripción completa

Detalles Bibliográficos
Autores principales: Schumacher, Dominik, Hackenberger, Christian P. R., Leonhardt, Heinrich, Helma, Jonas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2016
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4891387/
https://www.ncbi.nlm.nih.gov/pubmed/27003914
http://dx.doi.org/10.1007/s10875-016-0265-6
_version_ 1782435260394373120
author Schumacher, Dominik
Hackenberger, Christian P. R.
Leonhardt, Heinrich
Helma, Jonas
author_facet Schumacher, Dominik
Hackenberger, Christian P. R.
Leonhardt, Heinrich
Helma, Jonas
author_sort Schumacher, Dominik
collection PubMed
description Antibody drug conjugates (ADCs), a promising class of cancer biopharmaceuticals, combine the specificity of therapeutic antibodies with the pharmacological potency of chemical, cytotoxic drugs. Ever since the first ADCs on the market, a plethora of novel ADC technologies has emerged, covering as diverse aspects as antibody engineering, chemical linker optimization and novel conjugation strategies, together aiming at constantly widening the therapeutic window for ADCs. This review primarily focuses on novel chemical and biotechnological strategies for the site-directed attachment of drugs that are currently validated for 2nd generation ADCs to promote conjugate homogeneity and overall stability.
format Online
Article
Text
id pubmed-4891387
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Springer US
record_format MEDLINE/PubMed
spelling pubmed-48913872016-06-17 Current Status: Site-Specific Antibody Drug Conjugates Schumacher, Dominik Hackenberger, Christian P. R. Leonhardt, Heinrich Helma, Jonas J Clin Immunol Article Antibody drug conjugates (ADCs), a promising class of cancer biopharmaceuticals, combine the specificity of therapeutic antibodies with the pharmacological potency of chemical, cytotoxic drugs. Ever since the first ADCs on the market, a plethora of novel ADC technologies has emerged, covering as diverse aspects as antibody engineering, chemical linker optimization and novel conjugation strategies, together aiming at constantly widening the therapeutic window for ADCs. This review primarily focuses on novel chemical and biotechnological strategies for the site-directed attachment of drugs that are currently validated for 2nd generation ADCs to promote conjugate homogeneity and overall stability. Springer US 2016-03-22 2016 /pmc/articles/PMC4891387/ /pubmed/27003914 http://dx.doi.org/10.1007/s10875-016-0265-6 Text en © The Author(s) 2016 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Article
Schumacher, Dominik
Hackenberger, Christian P. R.
Leonhardt, Heinrich
Helma, Jonas
Current Status: Site-Specific Antibody Drug Conjugates
title Current Status: Site-Specific Antibody Drug Conjugates
title_full Current Status: Site-Specific Antibody Drug Conjugates
title_fullStr Current Status: Site-Specific Antibody Drug Conjugates
title_full_unstemmed Current Status: Site-Specific Antibody Drug Conjugates
title_short Current Status: Site-Specific Antibody Drug Conjugates
title_sort current status: site-specific antibody drug conjugates
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4891387/
https://www.ncbi.nlm.nih.gov/pubmed/27003914
http://dx.doi.org/10.1007/s10875-016-0265-6
work_keys_str_mv AT schumacherdominik currentstatussitespecificantibodydrugconjugates
AT hackenbergerchristianpr currentstatussitespecificantibodydrugconjugates
AT leonhardtheinrich currentstatussitespecificantibodydrugconjugates
AT helmajonas currentstatussitespecificantibodydrugconjugates

Ejemplares similares